Drugs / Metabolically Armed BCMA CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07085559 | Jun 2025 → Jun 2027 expected | AL amyloidosis, plasma cell leukemia, plasma cell myeloma | Anhui Provincial Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metabolically Armed BCMA CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07085559 ↗ |
| Modality | Cell therapy | “metabolically armed BCMA CAR-T cells” NCT07085559 ↗ |
| Route | Intravenous | “Each subject receive metabolically armed BCMA CAR- T cells by intravenous infusion.” NCT07085559 ↗ |